Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Covington
Deloitte
Accenture
Teva
Queensland Health
Boehringer Ingelheim
Federal Trade Commission
QuintilesIMS
UBS

Generated: October 22, 2017

DrugPatentWatch Database Preview

Osmotica Company Profile

« Back to Dashboard

What is the competitive landscape for OSMOTICA, and when can generic versions of OSMOTICA drugs launch?

OSMOTICA has nine approved drugs.

There are two US patents protecting OSMOTICA drugs.

There are eighty-seven patent family members on OSMOTICA drugs in forty-four countries and two supplementary protection certificates in two countries.

Summary for Applicant: Osmotica

International Patents:87
US Patents:2
Tradenames:8
Ingredients:8
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Osmotica Pharm Us
NIFEDIPINE
nifedipine
TABLET, EXTENDED RELEASE;ORAL077410-001Oct 3, 2007AB2RXNoNo► Subscribe► Subscribe► Subscribe
Osmotica Pharm Us
OXYBUTYNIN CHLORIDE
oxybutynin chloride
TABLET, EXTENDED RELEASE;ORAL078503-001Feb 4, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-001May 20, 2008ABRXYesNo► Subscribe► Subscribe ► Subscribe
Osmotica
METHYLPHENIDATE HYDROCHLORIDE
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL205327-005Jul 28, 2017RXNoNo► Subscribe► Subscribe► Subscribe
Osmotica
OMTRYG
omega-3-acid ethyl esters type a
CAPSULE;ORAL204977-001Apr 23, 2014DISCNYesNo► Subscribe► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-004May 20, 2008ABRXYesNo► Subscribe► Subscribe ► Subscribe
Osmotica Pharm Us
NIFEDIPINE
nifedipine
TABLET, EXTENDED RELEASE;ORAL077127-002Nov 21, 2005AB2RXNoNo► Subscribe► Subscribe► Subscribe
Osmotica
METHYLPHENIDATE HYDROCHLORIDE
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL205327-002Jul 28, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Osmotica
HYDROMORPHONE HYDROCHLORIDE
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL205629-003Jul 7, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Osmotica Pharm Us
DONEPEZIL HYDROCHLORIDE
donepezil hydrochloride
TABLET;ORAL203114-001Jan 26, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Osmotica

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-003May 20, 2008► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-001May 20, 2008► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-002May 20, 2008► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-004May 20, 2008► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-003May 20, 2008► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-004May 20, 2008► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-001May 20, 2008► Subscribe► Subscribe
Osmotica Pharm
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
TABLET, EXTENDED RELEASE;ORAL022104-002May 20, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Osmotica

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,274,171 Extended release formulation of venlafaxine hydrochloride► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Osmotica Drugs

Country Document Number Estimated Expiration
Estonia04577► Subscribe
Slovenia1028718► Subscribe
South Africa9810081► Subscribe
Brazil9813179► Subscribe
Hungary0004287► Subscribe
Peru128699► Subscribe
Norway20050379► Subscribe
South Korea101096512► Subscribe
European Patent Office1028718► Subscribe
Turkey9700190► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Osmotica Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1998Austria► SubscribePRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
C/GB97/023United Kingdom► SubscribePRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
US Department of Justice
Johnson and Johnson
Deloitte
Medtronic
QuintilesIMS
UBS
AstraZeneca
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot